Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CPP2022-009937

Financiado

Cerrado

Cáncer

The proposed project entitled "Development and evaluation of the predictive value of an ultra-sensitive Next Generation Sequencing (NGS) test for the detection of Minimal Residual Disease (MRD) after efficient treatments in differ... ver más

01/01/2022

ALTUM SEQUENCING

200K€

Presupuesto del proyecto: 200K€

Líder del proyecto

ALTUM SEQUENCING Realización de actividades de investigación, innovación, estudio, captación de datos y desarrollo en el ámbito de la biotecnología para la e...

TRL 5-6 | 260K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo AGENCIA ESTATAL DE INVESTIGACIÓN notifico la concesión del proyecto el día 2022-01-01 No tenemos la información de la convocatoria

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ALTUM SEQUENCING

200.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

ALTUM SEQUENCING Realización de actividades de investigación, innovación, estudio, captación de datos y desarrollo en el ámbito de la biotecnología para la e...

TRL 5-6 | 260K€

Presupuesto del proyecto 200K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The proposed project entitled "Development and evaluation of the predictive value of an ultra-sensitive Next Generation Sequencing (NGS) test for the detection of Minimal Residual Disease (MRD) after efficient treatments in different liquid biopsies, including blood, urine, and saliva, is a strategic plan for the expansion of Altum Sequencing. This project will be directly coordinated by the COO, Yanira Heredia, and the CEO of Altum, Santiago Barrio, also principal investigator at the Hospital 12 de Octubre in Madrid.Altum Sequencing is a spin-off born in April 2019 through the Research Foundation of the Hospital 12 de Octubre (H12O). Altum was founded by an experienced team with a strong clinical, scientific and management backgrounds. Altum is directly linked to the hematology and oncology departments of the H12O. The intellectual property has been transferred from this center to Altum for its commercial exploitation. Altum arises to meet the relentless need to reduce relapses and deaths of cancer patients. Despite the recent development of new effective treatments have improved the clinical outcome, 70% of cancer patients eventually stop responding and relapse. These relapses are due to the presence of tumor cells that survive the therapy, called Minimal Residual Disease (MRD), undetectable by conventional technologies.Altum has developed and commercialized CloneSight, an universal, non-invasive and cost-efficient test to detect MRD with unprecedented sensitivity. In this project, Altum will collaborate with the Research Foundation of the H12O, particularly with the Translational Clinical Oncology Unit, the Uro-Oncology Unit and Basic & Traslational Oncology Unit to develop three liquid biopsy MRD tests for urgent clinical needs. As first aim, we will apply the Altum's technology to three different types of liquid biopsies, blood, urine and saliva. The ability of each test to identify high-risk patients after curative intent treatment will be assessed in three clinical cohorts: 1) In blood from stage I-III non squasmous cell lung carcinoma collected after curative tumor resection. 2) In urine supernatant from localized non muscle-invasive bladder cancer patients collected after surgical tumor resection 3) In saliva from stage III-IV oral squamous cell carcinoma patients collected after surgery with curative intent. As a second aim, the ability of the tests to detect early tumor progression will also be evaluated during follow-up. A highly qualified interdisciplinary team has been created to achieve the aims of this proposal. Access to patients, samples, clinical data and facilities is only possible if clinical research units are involved. The technology and its commercial exploitation and certification are only guaranteed if a private company takes the reins.Altum is already operating as a certified laboratory with different clients, including pharmaceutical companies such as Incyte, Wugen, Janssen or Novartis, specialized clinical groups (PETHEMA), and CROss such as Medsir or Apices and cancer foundations such as Cris. Since its foundation in April 2019, Altum has obtained 372,000 in public aid, which has allowed the commercialization of CloneSight-MRD (test to monitor the existence of cancer cells after treatment) in international markets. In addition, Altum licensed CloneSight to Chinese company called Hosea Precision Medical for its commercial exploitation in the Asian market. The final aim of this project is to provide cancer patients with the best treatment and surveillance strategy to improve survival and quality of life. SENSORIAL\APP\LABORATORIO\DOLOR\MIGRAÑA\AVERSION\HIPERSENSIBILIDAD\SONIDO\LUZ\UMBRALES

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores